NEW YORK, April 16, 2013 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 <\/p>\n
http:\/\/www.reportlinker.com\/p01158447\/EpiCast-Report-Psoriasis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> <\/p>\n EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 <\/p>\n Summary <\/p>\n Psoriasis is an immune-mediated chronic disorder of the skin characterized by redness and irritation. It affects people of both sexes and of all ages and races\/ethnicities. The global prevalence of psoriasis varies geographically, with the disease being more prevalent in the colder areas of the north, and less prevalent in the tropics and warmer regions of the world (Weller et al., 2008). In European countries, psoriasis is more prevalent in residents of the colder central regions and less prevalent in residents of the southern regions. In some Asian countries, such as India, the prevalence of psoriasis is highest in the northern parts of the country. In contrast to India, China shows no difference in prevalence between the northern and southern regions (Bedi, 1995; Ding et al., 2012; Kawada et al., 2003; Naldi et al., 2004; Saraceno et al., 2006). In addition to the north-to-south prevalence gradient observed within most countries, the prevalence of psoriasis also varies among different countries. Globally, the prevalence of psoriasis varies from as low as 0.03% in Japan to as high as 3.15% in the US (Ding et al., 2012; Kawada et al., 2003). Differences in the reported prevalence between countries may be attributable to variations in environmental factors, genetic factors, and differences in the case definition used to diagnose psoriasis in epidemiology studies (Bedi, 1995; Ding et al., 2012; Gelfand et al., 2005b). <\/p>\n Scope <\/p>\n - The Psoriasis EpiCast Report provides an overview of the risk factors and global trends of psoriasis in the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India). - It includes a 10-year epidemiology forecast of the prevalent cases of psoriasis segmented by sex and age (by five-year increments, beginning at age 15 years and ending at =85 years) in the 9MM. <\/p>\n Reasons to buy <\/p>\n - Develop business strategies by understanding the trends shaping and driving the global psoriasis market. - Quantify patient populations in the global psoriasis market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for psoriasis therapeutics in each of the markets covered.<\/p>\n <\/p>\n Follow this link: NEW YORK, April 16, 2013 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 http:\/\/www.reportlinker.com\/p01158447\/EpiCast-Report-Psoriasis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 Summary Psoriasis is an immune-mediated chronic disorder of the skin characterized by redness and irritation. It affects people of both sexes and of all ages and races\/ethnicities Continue reading
\nEpiCast Report: Psoriasis - Epidemiology Forecast to 2022<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"